Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Robert F. Kennedy Jr’s confirmation hearings are set to begin Wednesday before the Senate Finance Committee and the Health, ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

President Donald Trump signed the bipartisan Laken Riley Act into law as his administration’s first piece of legislation.

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...